✉ Email this page to a colleague
« Back to Dashboard
▶ Start for $1
Remove trial restrictions
TA-8995 is an investigational drug.
There have been 9 clinical trials for TA-8995. The most recent clinical trial was a Phase 2 trial, which was initiated on August 1st 2013.
The most common disease conditions in clinical trials are Dyslipidemias, Alzheimer Disease, and [disabled in preview]. The leading clinical trial sponsors are Xention Ltd, Mitsubishi Tanabe Pharma Corporation, and NewAmsterdam Pharma.
There are three US patents protecting this investigational drug and seventy-eight international patents.
Recent Clinical Trials for TA-8995
|Proof-of-concept, Open-label Study in Patients With Early Alzheimer's Disease||NewAmsterdam Pharma||Phase 2|
|Bioequivalence Study of Capsule and Tablet Formulations of TA-8995||Xention Ltd||Phase 1|
|ADME Study in Healthy Male Subjects With TA-8995||Xention Ltd||Phase 1|
Top disease conditions for TA-8995
Top clinical trial sponsors for TA-8995
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|TA-8995||See Plans and Pricing||Process for preparing synthetic intermediates for preparing tetrahydroquinoline derivatives||DEZIMA PHARMA B.V. (Naarden, NL)||See Plans and Pricing|
|TA-8995||See Plans and Pricing||Pharmaceutical composition and therapeutic combination comprising a cholesteryl ester transfer protein inhibitor and HMG CoA reductase inhibitors||DEZIMA PHARMA B.V. (NL)||See Plans and Pricing|
|TA-8995||See Plans and Pricing||Cholesteryl ester transfer protein (CETP) inhibitor and pharmaceutical compositions comprising said inhibitor for use in the treatment or prevention of cardiovascular diseases||DEZIMA PHARMA BV (NL)||See Plans and Pricing|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|TA-8995||Argentina||AR101509||2034-08-12||See Plans and Pricing|
|TA-8995||Australia||AU2015302407||2034-08-12||See Plans and Pricing|
|TA-8995||Brazil||BR112017002873||2034-08-12||See Plans and Pricing|
|TA-8995||Canada||CA2958040||2034-08-12||See Plans and Pricing|
|TA-8995||Chile||CL2017000367||2034-08-12||See Plans and Pricing|
|TA-8995||China||CN107108558||2034-08-12||See Plans and Pricing|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|